Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 61 | 4 | 753-758

Article title

Ovocystatin affects actin cytoskeleton organization and induces proapoptotic activity

Content

Title variants

Languages of publication

EN

Abstracts

EN
Ovocystatin is a chicken egg white protein, generally known for its inhibitory activity against cysteine proteases. However, biological activity of ovocystatin does not seem to be well recognized in respect to other possible cellular effects. Our attention has been focused on ovocystatin cytotoxic effects in relation to its influence on actin cytoskeleton organization and apoptosis induction. In vitro studies with human melanoma A375, human cervix HeLa cancer cells and normal human fibroblasts - NHDF were done. Cytotoxic activity of ovocystatin was seen in respect to apoptosis induction - manifested by cell shape changes, phosphatydylserine translocation and actin cytoskeleton reorganization. Normal human fibroblasts have shown lower sensitivity to ovocystatin as compared with human melanoma A375 and human cervix HeLa cancer cells. In conclusion, ovocystatin affects actin cytoskeleton organization and displays proapoptotic activity towards applied cell lines. This implicates its application as a potential anticancer drug. However, its adverse effects on normal cells should be taken into consideration.

Year

Volume

61

Issue

4

Pages

753-758

Physical description

Dates

published
2014
received
2014-01-28
revised
2014-05-28
accepted
2014-06-14
(unknown)
2014-09-03

Contributors

  • Department of Cell Pathology, Faculty of Biotechnology, University of Wrocław, Wrocław, Poland
  • Department of Cell Pathology and Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wrocław, Wrocław, Poland
  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland
  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland
  • Department of Pathophysiology, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland
author
  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Wrocław Medical University, Wrocław, Poland

References

  • Abrahamson M, Alvarez-Fernandez M, Nathanson CM (2003) Cystatins. Biochem Soc Symp 70: 179-199.
  • Anastasi A, Brown MA, Kembhavi AA, Nicklin MJH, Sayers CA, Sunter DC, Barrett AJ (1983) Cystatin, a protein inhibitor of cysteine proteinases. Biochem J 211: 129-138.
  • Arteaga CL (2006) Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 16: 30-37.
  • Barrett AJ (1972) A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem 47: 280-293.
  • Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y (1994) Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 211: 314-321.
  • Bode W, Engh R, Musil D, Thiele U, Huber R, Karshikov A, Brzin J, Kos J, Turk V (1988) The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J 7: 2593-2599.
  • Chwieralski CE, Welte T, Bühling F (2006) Cathepsin-regulated apoptosis. Apoptosis 11: 143-149.
  • Gole B, Huszthy PC, Popović M, Jeruc J, Ardebili YS, Bjerkvig R, Lah TT (2012) The regulation of cysteine cathepsins and cystatins in human gliomas. Int J Cancer 131: 1779-1789.
  • Gołąb K, Gburek J, Juszczyńska K, Trziszka T, Polanowski A (2012) Stabilization of monomeric chicken egg white cystatin. Przemysł Chemiczny 91: 741-744.
  • Liang X, Nagai A, Terashima M, Sheikh AM, Shiota Y, Mitaki S, Kim SU, Yamaguchi S (2011) Cystatin C induces apoptosis and tyrosine hydroxylase gene expression through JNK-dependent pathway in neuronal cells. Neurosci Lett 496: 100-105.
  • Liu Z, Jang SW, Liu X, Cheng D, Peng J, Yepes M, Li XJ, Matthews S, Watts C, Asano M, Hara-Nishimura I, Luo HR, Ye K (2008) Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol Cell 29: 665-678.
  • Magister Š, Kos J (2013) Cystatins in immune system. J Cancer 4: 45-56.
  • Majewska E, Wittek N, Rysz J, Baj Z (2012) The influence of uremic high cystatin C concentration on neutrophil apoptosis and selected neutrophil functions isolated from healthy subjects. Med Sci Monit 18: CR667-CR673.
  • Mosmann T (1973) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 65: 55-63.
  • Ochieng J, Chaudhuri G (2010) Cystatin superfamily. J Health Care Poor Underserved 21: 51-70.
  • Radwańska A, Baczyńska D, Nowak D, Brézillon S, Popow A, Maquart FX, Wegrowski Y, Malicka-Blaszkiewicz M (2008) Lumican affects actin cytoskeletal organization in human melanoma A375 cells. Life Sci 83: 651-660.
  • Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R (2012) Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Biochimie 94: 2590-2599.
  • Tian M, Schiemann WP (2009) Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer. Transl Oncol 2: 174-183.
  • Tombaccini D, Mocali A, Weber E, Paoletti F (2001) A cystatin-based affinity procedure for the isolation and analysis of papain-like cysteine proteinases from tissue extracts. Anal Biochem 289: 231-238.
  • Turk V, Stoka V, Turk D (2008) Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 13: 5406-5420.
  • Vasiljeva O, Reinheckel T, Peters C (2007) Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13: 387-403.
  • Wallin H, Abrahamson M, Ekström U (2013) Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes. J Biol Chem 288: 17019-17029
  • Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, Bjartell A (2009) Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One 4: e7953.
  • Yu W, Liu J, Shi MA, Wang J, Xiang M, Kitamoto S, Wang B, Sukhova GK, Murphy GF, Orasanu G, Grubb A, Shi GP (2010) Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice. PLoS One 5: e13973.
  • Zavašnik-Bergant T (2008) Cystatin protease inhibitors and immune functions. Front Biosci 13: 4625-4637.

Document Type

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.bwnjournal-article-abpv61p753kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.